Название продукции:6,7-dimethoxyquinolin-4-ol
IUPAC Name:6,7-dimethoxyquinolin-4-ol
- CAS：13425-93-9
- Молекулярная формула：C11H11NO3
- Чистота：97%
- Номер в каталоге：CM104728
- Молекулярная масса：205.21
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:13425-93-9
- Молекулярная формула:C11H11NO3
- Точка плавления:-
- Smiles-код:COC1=C(OC)C=C2C(O)=CC=NC2=C1
- Плотность:
- Номер в каталоге:CM104728
- Молекулярная масса:205.21
- Точка кипения:
- Номер Mdl:MFCD07368026
- Хранение:
Category Infos
- Quinolines
- Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
- Quinoline Price
- if you have any question on quinoline price, we will give the professional answers to your short questions.
Column Infos
- Cabozantinib
- On August 21, 2023, Exelixis and Ipsen announced that the global phase 3 CONTACT-02 study of cabozantinib (Cabometyx ®) in combination with atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) met the primary endpoint of progression-free survival (PFS) in an interim analysis.
Prostate cancer is the fourth most common cancer worldwide and the second most common cancer among men. At present, the drugs approved for the treatment of CRPC are basically AR inhibitors or PARP inhibitors, and the combination therapy of Cabozantinib + Atezolizumab is expected to become a new treatment option for such patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Поиск 
+86 21 5895 0110 
